PortalPublikationenBody Mass Index Is Prognostic in Metastatic Colorectal Cance...

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database

Standard

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. / Renfro, Lindsay A; Loupakis, Fotios; Adams, Richard A; Seymour, Matthew T; Heinemann, Volker; Schmoll, Hans-Joachim; Douillard, Jean-Yves; Hurwitz, Herbert; Fuchs, Charles S; Diaz-Rubio, Eduardo; Porschen, Rainer; Tournigand, Christophe; Chibaudel, Benoist; Falcone, Alfredo; Tebbutt, Niall C; Punt, Cornelis J A; Hecht, J Randolph; Bokemeyer, Carsten; Van Cutsem, Eric; Goldberg, Richard M; Saltz, Leonard B; de Gramont, Aimery; Sargent, Daniel J; Lenz, Heinz-Josef.

in: J CLIN ONCOL, Jahrgang 34, Nr. 2, 01.2016, S. 144-150.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Renfro, LA, Loupakis, F, Adams, RA, Seymour, MT, Heinemann, V, Schmoll, H-J, Douillard, J-Y, Hurwitz, H, Fuchs, CS, Diaz-Rubio, E, Porschen, R, Tournigand, C, Chibaudel, B, Falcone, A, Tebbutt, NC, Punt, CJA, Hecht, JR, Bokemeyer, C, Van Cutsem, E, Goldberg, RM, Saltz, LB, de Gramont, A, Sargent, DJ & Lenz, H-J 2016, 'Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database', J CLIN ONCOL, Jg. 34, Nr. 2, S. 144-150. https://doi.org/10.1200/JCO.2015.61.6441

APA

Renfro, L. A., Loupakis, F., Adams, R. A., Seymour, M. T., Heinemann, V., Schmoll, H-J., Douillard, J-Y., Hurwitz, H., Fuchs, C. S., Diaz-Rubio, E., Porschen, R., Tournigand, C., Chibaudel, B., Falcone, A., Tebbutt, N. C., Punt, C. J. A., Hecht, J. R., Bokemeyer, C., Van Cutsem, E., ... Lenz, H-J. (2016). Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J CLIN ONCOL, 34(2), 144-150. https://doi.org/10.1200/JCO.2015.61.6441

Vancouver

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll H-J et al. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J CLIN ONCOL. 2016 Jan;34(2):144-150. https://doi.org/10.1200/JCO.2015.61.6441

Bibtex

@article{ceeb29c62b5146e3b764e5633bdee54b,
title = "Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database",
abstract = "PURPOSE: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear.PATIENTS AND METHODS: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted).RESULTS: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect.CONCLUSION: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.",
author = "Renfro, {Lindsay A} and Fotios Loupakis and Adams, {Richard A} and Seymour, {Matthew T} and Volker Heinemann and Hans-Joachim Schmoll and Jean-Yves Douillard and Herbert Hurwitz and Fuchs, {Charles S} and Eduardo Diaz-Rubio and Rainer Porschen and Christophe Tournigand and Benoist Chibaudel and Alfredo Falcone and Tebbutt, {Niall C} and Punt, {Cornelis J A} and Hecht, {J Randolph} and Carsten Bokemeyer and {Van Cutsem}, Eric and Goldberg, {Richard M} and Saltz, {Leonard B} and {de Gramont}, Aimery and Sargent, {Daniel J} and Heinz-Josef Lenz",
note = "{\textcopyright} 2015 by American Society of Clinical Oncology.",
year = "2016",
month = jan,
doi = "10.1200/JCO.2015.61.6441",
language = "English",
volume = "34",
pages = "144--150",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

RIS

TY - JOUR

T1 - Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database

AU - Renfro, Lindsay A

AU - Loupakis, Fotios

AU - Adams, Richard A

AU - Seymour, Matthew T

AU - Heinemann, Volker

AU - Schmoll, Hans-Joachim

AU - Douillard, Jean-Yves

AU - Hurwitz, Herbert

AU - Fuchs, Charles S

AU - Diaz-Rubio, Eduardo

AU - Porschen, Rainer

AU - Tournigand, Christophe

AU - Chibaudel, Benoist

AU - Falcone, Alfredo

AU - Tebbutt, Niall C

AU - Punt, Cornelis J A

AU - Hecht, J Randolph

AU - Bokemeyer, Carsten

AU - Van Cutsem, Eric

AU - Goldberg, Richard M

AU - Saltz, Leonard B

AU - de Gramont, Aimery

AU - Sargent, Daniel J

AU - Lenz, Heinz-Josef

N1 - © 2015 by American Society of Clinical Oncology.

PY - 2016/1

Y1 - 2016/1

N2 - PURPOSE: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear.PATIENTS AND METHODS: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted).RESULTS: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect.CONCLUSION: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.

AB - PURPOSE: In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear.PATIENTS AND METHODS: Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted).RESULTS: BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m(2), and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect.CONCLUSION: Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.

U2 - 10.1200/JCO.2015.61.6441

DO - 10.1200/JCO.2015.61.6441

M3 - SCORING: Journal article

C2 - 26503203

VL - 34

SP - 144

EP - 150

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 2

ER -